Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05655091 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Target Attainment of Continuous Infusion Flucloxacillin and Cefazolin Coupled With TDM vs. Standard of Care Treatment in Patients With Complicated S. Aureus Infection

Study acronym: TARGET III
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 16, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Apr 2024 to Dec 2025v5
  2. Start date: Oct 23, 2023 to Oct 26, 2023v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 2023 to Oct 23, 2023
    • Site details revised
    v3
  4. Start date: Feb 2023 to Aug 2023v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This prospective randomized, controlled interventional pilot trial, aims to compare the achievement of the optimal target concentration with continuously administered flucloxacillin (FLU) or cefazolin (CZO) coupled with TDM and subsequent dose adjustment versus standard of care (intermittent bolus application without TDM-guidance) in patients with complicated Staphylococcus aureus (S. aureus) infections (CSAI). The overall goal is to individualize and optimize antibiotic treatment in a very vulnerable group of patients overcoming the standard strategy of "one-dose-fits-all".
Trial Details
NCT Number NCT05655091
Lead Sponsor University Hospital, Basel, Switzerland
Conditions
(from sponsor)		 Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI)
Related terms Infections, Staphylococcal Infections
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov